A federal judge dismissed AbCellera Biologics Inc.’s lawsuit against Bruker Cellular Analysis Inc. over technology used to discover antibodies for preventing and treating diseases, finding it failed to offer enough evidence to show how Bruker’s microfluidic devices infringe fifteen patents.
Judge Jon S. Tigar agreed with Bruker’s argument that the consolidated complaint fails to plausibly allege how the accused products and services meet every assaying step in the asserted patents, according to an opinion issued Thursday in the US District Court for the Northern District of California. He granted Bruker’s motion but gave AbCellera and the University of British Columbia, ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.